White KE - Search Results

1

A rat model of chronic kidney disease-mineral bone disorder.

Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH 2nd. Moe SM, et al. Among authors: white ke. Kidney Int. 2009 Jan;75(2):176-84. doi: 10.1038/ki.2008.456. Epub 2008 Sep 17. Kidney Int. 2009. PMID: 18800026 Free PMC article.

2

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. White KE, et al. Kidney Int. 2001 Dec;60(6):2079-86. doi: 10.1046/j.1523-1755.2001.00064.x. Kidney Int. 2001. PMID: 11737582 Free article.

3

The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.

Moe SM, Radcliffe JS, White KE, Gattone VH 2nd, Seifert MF, Chen X, Aldridge B, Chen NX. Moe SM, et al. Among authors: white ke. J Bone Miner Res. 2011 Nov;26(11):2672-81. doi: 10.1002/jbmr.485. J Bone Miner Res. 2011. PMID: 21826734 Free article.

4

Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Clinkenbeard EL, Noonan ML, Thomas JC, Ni P, Hum JM, Aref M, Swallow EA, Moe SM, Allen MR, White KE. Clinkenbeard EL, et al. Among authors: white ke. JCI Insight. 2019 Feb 21;4(4):e123817. doi: 10.1172/jci.insight.123817. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830862 Free PMC article.

5

Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).

Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, Allen MR, White KE. Noonan ML, et al. Among authors: white ke. Physiol Rep. 2020 Jun;8(11):e14434. doi: 10.14814/phy2.14434. Physiol Rep. 2020. PMID: 32476270 Free PMC article.

6

Targeting fibroblast growth factor 23-responsive pathways uncovers controlling genes in kidney mineral metabolism.

Ni P, Clinkenbeard EL, Noonan ML, Richardville JM, McClintick J, Hato T, Janosevic D, Cheng YH, El-Achkar TM, Eadon MT, Dagher PC, White KE. Ni P, et al. Among authors: white ke. Kidney Int. 2021 Mar;99(3):598-608. doi: 10.1016/j.kint.2020.10.024. Epub 2020 Nov 4. Kidney Int. 2021. PMID: 33159963 Free PMC article.

7

Age and sex effects on FGF23-mediated response to mild phosphate challenge.

Tippen SP, Noonan ML, Ni P, Metzger CE, Swallow EA, Sacks SA, Chen NX, Thompson WR, Prideaux M, Atkins GJ, Moe SM, Allen MR, White KE. Tippen SP, et al. Among authors: white ke. Bone. 2021 May;146:115885. doi: 10.1016/j.bone.2021.115885. Epub 2021 Feb 19. Bone. 2021. PMID: 33618073 Free PMC article.

8

Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics.

Agoro R, White KE. Agoro R, et al. Among authors: white ke. Curr Opin Nephrol Hypertens. 2022 Jul 1;31(4):320-325. doi: 10.1097/MNH.0000000000000797. Epub 2022 Jun 10. Curr Opin Nephrol Hypertens. 2022. PMID: 35703246 Free PMC article. Review.

9

A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.

Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE. Larsson T, et al. Among authors: white ke. J Clin Endocrinol Metab. 2005 Apr;90(4):2424-7. doi: 10.1210/jc.2004-2238. Epub 2005 Feb 1. J Clin Endocrinol Metab. 2005. PMID: 15687325

10

Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations.

Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Yu X, et al. Among authors: white ke. Bone. 2005 Jun;36(6):971-7. doi: 10.1016/j.bone.2005.03.002. Bone. 2005. PMID: 15869926

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235 results

Search Page

Filters